Expertise in
8
conditions

Tao Yang

2666 Ludang Road, 
Suzhou, CN 
Expertise in
8
conditions
2666 Ludang Road, 
Suzhou, CN 

Overview

Tao Yang practices practicing medicine in Suzhou, China.

Yang is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Type 1 Diabetes (T1D), Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Gallbladder Removal, and Islet Cell Transplantation.

They are actively involved in clinical research, co-authoring 387 peer reviewed articles and participating in 6 clinical trials.

Locations

2666 Ludang Road, Suzhou, 215200, China
Other Locations
209 Tongshan Road, Xuzhou, 221004, China
#300 Guangzhou Road, Nanjing, 210029, China
600 South Wan Ping Rd, Shanghai, 200030, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug
Study Drug: Rituximab
Study Phase: Phase 4
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus
A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: March 29, 2021
Intervention Type: Drug
Study Phase: Phase 3
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

387 Total Publications

3D-printed niche-matched GelMA-dECM bioinks rewire lipid metabolic reprogramming and chemosensitization in pancreatic ductal adenocarcinoma.
3D-printed niche-matched GelMA-dECM bioinks rewire lipid metabolic reprogramming and chemosensitization in pancreatic ductal adenocarcinoma.
Journal: Biomaterials
Published: June 04, 2026

Frequently Asked Questions about Tao Yang

Is Tao Yang a top-rated expert for Type 1 Diabetes (T1D)?

MediFind is an objective health platform that identifies experts based on real-world data. Tao Yang is classified as an Distinguished expert for Type 1 Diabetes (T1D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tao Yang participate in research or clinical trials?

Yes. Tao Yang has published 387 articles and abstracts on conditions like Type 1 Diabetes (T1D). You can view a list of Tao Yang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yang's expertise for a condition
ConditionClose
    View All 51 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile